STOCK TITAN

Nautilus Biotechnology Inc - NAUT STOCK NEWS

Welcome to our dedicated news page for Nautilus Biotechnology (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nautilus Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nautilus Biotechnology's position in the market.

Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported Q2 2023 financial results, highlighting a 23% increase in operating expenses and a net loss of $15.8 million. The company's CEO, Sujal Patel, expressed excitement about progress made in foundational scientific and development goals, with a focus on preparations for a commercial launch in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Summary
Nautilus Biotechnology, Inc. will report financial results for the second quarter on August 2, 2023. The company's management will host a conference call to discuss the results and business developments. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
Rhea-AI Summary
Nautilus Biotechnology reports financial results for Q1 2023, announces winners of First Access Challenge, and receives new US Patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.31%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
Nautilus Biotechnology Inc

Nasdaq:NAUT

NAUT Rankings

NAUT Stock Data

308.99M
40.97M
33.65%
49.78%
0.96%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States
Seattle

About NAUT

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.